AI CuratorAI-generated
Research summary · AI summary · not yet reviewedAnimal studyPreclinicalPublished in a peer-reviewed journal
Mouse Study on Acetalated Dextran Microparticles Targeting B Cells
In a preclinical model of multiple sclerosis using mice, treatment with acetalated dextran microparticles (Ace-DEX MPs) targeting B cells resulted in a significant decrease in clinical symptoms related to the disease.
- Tags
- #MSResearch
- Most relevant to
- —
This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.
- Human efficacy
- Not yet tested in people
- Mechanism
- Not reported
- Evidence strength
- Early – laboratory or animal research
- Outcome
- Not reported
Results in cells or animals often do not carry over to people with MS.
Why it matters
This research suggests that Ace-DEX MPs could be a potential approach for targeting B cells in multiple sclerosis. Successful targeting may lead to new therapeutic strategies.
What this does not prove
The study only assessed the effects in a preclinical model, not in human subjects.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Laboratory
- Participants / samples
- Not reported
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- Not reported
- Publication date
- 2026-10-23
- Evidence reviewed
- Abstract only
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Experimental autoimmune encephalomyelitis (EAE) model
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Primary evidencePhysicochemical design principles for B cell targeted acetalated dextran microparticles in antigen-specific tolerance for multiple sclerosis. ↗DOI: 10.1039/d6bm01160h
Supporting passages (11)
study phaseThe Ace-DEX MPs (AMPs) were evaluated in a preclinical MS model (experimental autoimmune encephalomyelitis (EAE)) using an adoptive transfer of ex vivo B cells surface decorated with MOG35-55 loaded AMPs and achieved a significant decrease in the clinical score.
study designThis work demonstrates the role of polymer properties in B cell binding and outcomes as an antigen-specific therapeutic vaccine.
subjectsThe Ace-DEX MPs (AMPs) were evaluated in a preclinical MS model (experimental autoimmune encephalomyelitis (EAE)) using an adoptive transfer of ex vivo B cells surface decorated with MOG35-55 loaded AMPs and achieved a significant decrease in the clinical score.
speciesThe Ace-DEX MPs (AMPs) were evaluated in a preclinical MS model (experimental autoimmune encephalomyelitis (EAE)) using an adoptive transfer of ex vivo B cells surface decorated with MOG35-55 loaded AMPs and achieved a significant decrease in the clinical score.
peer reviewedPublication types: Journal Article
interventionMicroparticles comprised of the polymer acetalated dextran (Ace-DEX) bind to B cells more efficiently than other biomaterial systems and reside at the surface without internalization due to microparticle size.
findingsachieved a significant decrease in the clinical score.
populationThe Ace-DEX MPs (AMPs) were evaluated in a preclinical MS model (experimental autoimmune encephalomyelitis (EAE)) using an adoptive transfer of ex vivo B cells surface decorated with MOG35-55 loaded AMPs and achieved a significant decrease in the clinical score.
publication datePublication date: 2026-10-23
limitationsTitle: Physicochemical design principles for B cell targeted acetalated dextran microparticles in antigen-specific tolerance for multiple sclerosis.
human efficacyThe Ace-DEX MPs (AMPs) were evaluated in a preclinical MS model (experimental autoimmune encephalomyelitis (EAE)) using an adoptive transfer of ex vivo B cells surface decorated with MOG35-55 loaded AMPs and achieved a significant decrease in the clinical score.
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.